Nyxoah SA (FRA:5YI)
Germany
· Delayed Price · Currency is EUR 4.160
+0.150 (3.74%)
At close: Dec 5, 2025
Nyxoah Company Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| Industry | Surgical and Medical Instruments and Apparatus |
| Employees | 184 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 022 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | 5YI |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer |
| John Landry | Chief Financial Officer |
| Mikaela Kirkwood | Head of Investor Relations |